概要
First, CRTH2+ cells are isolated by column-free immunomagnetic positive selection using antibody complexes and EasySep™ Releasable RapidSpheres™. Then, bound magnetic particles are removed from the EasySep™-isolated CRTH2+ cells, and unwanted non-ILC2s are targeted for depletion using antibody complexes and EasySep™ Dextran RapidSpheres™. The final isolated fraction contains highly purified ILC2s that are immediately ready for downstream applications.
Following cell isolation with this EasySep™ kit, antibody complexes remain bound to the cell surface and may interact with Brilliant Violet™ antibody conjugates, polyethylene glycol-modified proteins or other chemically related ligands.
技术资料
Document Type | 产品名称 | Catalog # | Lot # | 语言 |
---|---|---|---|---|
Product Information Sheet | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
Safety Data Sheet 1 | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
Safety Data Sheet 2 | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
Safety Data Sheet 3 | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
Safety Data Sheet 4 | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
Safety Data Sheet 5 | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
Safety Data Sheet 6 | EasySep™ Human ILC2 Isolation Kit | 17782 | All | English |
数据及文献
Data
Figure 1. Typical EasySep™ Human ILC2 Isolation Profile
Starting with fresh leukapheresis samples, the ILC2 content (CD45+Lin- CRTH2+CD161+CD127+) of the isolated fraction typically ranges from 84 - 95%. In the above example, the purities of the start and final isolated fractions are 0.03% and 91% (gated on CD45), respectively.